CORRECTED: Mylan's Inequitable Conduct Claim Axed In Vytorin IP Suit

Law360, San Francisco (May 19, 2011, 1:51 PM EDT) -- Schering Corp. on Tuesday won the dismissal of an inequitable conduct counterclaim by Mylan Pharmaceuticals Inc. in a ruling in Schering's lawsuit accusing the generic-drug maker of infringing its patents on cholesterol drug Vytorin. (A previous version of this article incorrectly stated that a ruling had been made on Mylan's antitrust counterclaims.)

U.S. District Judge Jose L. Linares granted Schering's bid to throw out Mylan's claim that it committed inequitable conduct by failing to disclose information to the U.S. Patent and Trademark Office.

According to the...
To view the full article, register now.